News

Published on 15 Feb 2024 on Insider Monkey via Yahoo Finance

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript


Article preview image

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript February 14, 2024

Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good morning. Welcome to SAGE Therapeutics' Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of SAGE’s website at SAGErx.com. This call is the property of SAGE Therapeutics and recording, reproduction or transmission of this call without the express written consent of SAGE Therapeutics, is strictly prohibited. Please note that this call is being recorded. I would now like to introduce Ashley Kaplowitz, Executive Director of Investor Relations and Capital Markets at SAGE.

NASDAQ.SAGE price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

Shares of Sage Pharmaceuticals SAGE dropped 19.6% on Wednesday after management shared topline re...

Zacks via Yahoo Finance 19 Apr 2024

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's...

Sage Therapeutics, Inc. (SAGE) is expected to deliver a year-over-year increase in earnings on hi...

Zacks via Yahoo Finance 19 Apr 2024

Sage halts trials in Parkinson’s after drug fails to show benefit - Boston Business Journal

Sage Therapeutics Inc. has decided to halt work on an experimental drugs in Parkinson’s disease...

The Business Journals 18 Apr 2024

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Dat...

Benzinga via Yahoo Finance 17 Apr 2024

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge By Benzinga

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge

Investing.com 17 Apr 2024

Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints

Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatmen...

Market Watch 17 Apr 2024

Sage stock drops after setback for Parkinson’s disease drug

Sage Therapeutics (SAGE) stock plummeted after the company's Phase 2 trial for Parkinson’s diseas...

Seeking Alpha 17 Apr 2024

Sage Therapeutics reports setback in Parkinson's study By Investing.com

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company, disclosed today that its Pha...

Investing.com 17 Apr 2024

12 Best All-Time Low Stocks To Invest In

In this piece, we will take a look at the 12 best all time low stocks to invest in. If you want t...

Insider Monkey via Yahoo Finance 11 Apr 2024

Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares hav...

Zacks via Yahoo Finance 15 Mar 2024